Moreover, the analysis of BCR-ABL-expressing stem cells in CML patients with sustained UMRD induced by 2nd generation TKIs must be performed, as these drugs generate molecular responses more rapidly than imatinib. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.